ConductScience.org, home

Trial · NCT03366298

Results by group21

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Plasma Catecholamine Levels (Maximum Concentration, Cmax)Emerade 300mcg Injection21895% Confidence Interval 132 to 359pg/ml
Plasma Catecholamine Levels (Maximum Concentration, Cmax)Emerade 500mcg Injection39495% Confidence Interval 310 to 500pg/ml
Plasma Catecholamine Levels (Maximum Concentration, Cmax)Epipen 0.3mg29095% Confidence Interval 200 to 421pg/ml
Plasma Catecholamine Levels (Time to Maximum Concentration, Tmax)Emerade 300mcg Injection9.695% Confidence Interval 5.3 to 17.4minutes
Plasma Catecholamine Levels (Time to Maximum Concentration, Tmax)Emerade 500mcg Injection8.595% Confidence Interval 6.1 to 11.8minutes
Plasma Catecholamine Levels (Time to Maximum Concentration, Tmax)Epipen 0.3mg5.995% Confidence Interval 4.9 to 7.3minutes
Plasma Catecholamine Levels (Maximum Concentration, Area-under-curve (AUC))Emerade 300mcg Injection17495% Confidence Interval 86 to 354hr*pg/ml
Plasma Catecholamine Levels (Maximum Concentration, Area-under-curve (AUC))Emerade 500mcg Injection38795% Confidence Interval 263 to 570hr*pg/ml
Plasma Catecholamine Levels (Maximum Concentration, Area-under-curve (AUC))Epipen 0.3mg20395% Confidence Interval 142 to 292hr*pg/ml
Adverse Events Following Self-administration of Adrenaline Via Autoinjector DeviceEmerade 300mcg InjectionPain at injection site8Participants
Adverse Events Following Self-administration of Adrenaline Via Autoinjector DeviceEmerade 500mcg InjectionPain at injection site6Participants
Adverse Events Following Self-administration of Adrenaline Via Autoinjector DeviceEpipen 0.3mgPain at injection site7Participants
Adverse Events Following Self-administration of Adrenaline Via Autoinjector DeviceEmerade 300mcg InjectionSystemic AE (any)4Participants
Adverse Events Following Self-administration of Adrenaline Via Autoinjector DeviceEmerade 500mcg InjectionSystemic AE (any)9Participants
Adverse Events Following Self-administration of Adrenaline Via Autoinjector DeviceEpipen 0.3mgSystemic AE (any)8Participants
Adverse Events Following Self-administration of Adrenaline Via Autoinjector DeviceEmerade 300mcg InjectionPalpitations3Participants
Adverse Events Following Self-administration of Adrenaline Via Autoinjector DeviceEmerade 500mcg InjectionPalpitations4Participants
Adverse Events Following Self-administration of Adrenaline Via Autoinjector DeviceEpipen 0.3mgPalpitations3Participants
Adverse Events Following Self-administration of Adrenaline Via Autoinjector DeviceEmerade 300mcg InjectionTremor3Participants
Adverse Events Following Self-administration of Adrenaline Via Autoinjector DeviceEmerade 500mcg InjectionTremor7Participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03366298/results